Mesoblast (MESO) Current Leases (2019 - 2026)
Mesoblast (MESO) posted Current Leases of $2.4 million for Q4 2025, down 11.12% sequentially from $2.7 million in Q2 2025, and little changed YoY from $2.4 million in Q4 2024.
Analysis
Mesoblast (MESO) Current Leases (2019 - 2026) Analysis & Trends
Mesoblast has reported Current Leases for 7 years, with the latest figure at $2.4 million in Q4 2025.
- Quarterly Current Leases changed 0.04% year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (changed 0.04% YoY) and the FY2025 annual result came in at $2.7 million, up 2.06% from the prior year.
- Current Leases declined to $2.4 million in Q4 2025 per MESO's latest filing, from $2.7 million in the prior quarter.
- Over five years, Current Leases peaked at $4.1 million in Q2 2023 and troughed at $2.4 million in Q4 2024.
- A 5-year average of $3.1 million and a median of $2.9 million in 2023 frame the typical range for Current Leases.
- The sharpest annual moves came in 2023 and 2024: Current Leases surged 48.29% in 2023, then slumped 35.32% in 2024.
- Over 5 years, Current Leases stood at $3.5 million in 2021, then gained by 10.63% to $3.9 million in 2022, then declined by 26.14% to $2.9 million in 2023, then fell by 16.49% to $2.4 million in 2024, then increased by 0.04% to $2.4 million in 2025.
- According to Business Quant data, Current Leases over the past three periods registered $2.4 million, $2.7 million, and $2.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | 5.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.07 Mn |
| Dec 31, 2025 | 5.89 Mn |
| Jun 30, 2025 | 3.58 Mn |
| Dec 31, 2024 | 4.75 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Dec 31, 2023 | 3.39 Mn |
| Jun 30, 2023 | 3.67 Mn |
| Mar 31, 2023 | 4.65 Mn |
| Dec 31, 2022 | 5.00 Mn |
| Sep 30, 2022 | 6.35 Mn |
| Jun 30, 2022 | 7.09 Mn |
| Mar 31, 2022 | 8.05 Mn |
| Dec 31, 2021 | 7.94 Mn |
| Sep 30, 2021 | 7.56 Mn |
| Jun 30, 2021 | 8.49 Mn |
| Mar 31, 2021 | 6.48 Mn |
| Dec 31, 2020 | 6.51 Mn |
| Sep 30, 2020 | 7.05 Mn |
| Jun 30, 2020 | 6.32 Mn |
| Mar 31, 2020 | 5.76 Mn |